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Abstract 
Background: Chemotherapy‑induced cardiotoxicity is a well‑recognized adverse effect of chemotherapy. Quantita‑
tive T1‑mapping cardiovascular magnetic resonance (CMR) is useful for detecting subclinical myocardial changes in 
anthracycline‑induced cardiotoxicity. The aim of the present study was to histopathologically validate the T1 and T2 
mapping parameters for the evaluation of diffuse myocardial changes in rat models of cardiotoxicity.
Methods: Rat models of cardiotoxicity were generated by injecting rats with doxorubicin (1 mg/kg, twice a week). 
CMR was performed with a 9.4 T ultrahigh‑field scanner using cine, pre‑T1, post‑T1 and T2 mapping sequences to 
evaluate the left ventricular ejection fraction (LVEF), native T1, T2, and extracellular volume fraction (ECV). Histopatho‑
logical examinations were performed and the association of histopathological changes with CMR parameters was 
assessed.
Results: Five control rats and 36 doxorubicin‑treated rats were included and classified into treatment periods. In the 
doxorubicin‑treated rats, the LVEF significantly decreased after 12 weeks of treatment (control vs. 12‑week treated: 
73 ± 4% vs. 59 ± 9%, P = 0.01).  Increased native T1 and ECV were observed after 6 weeks of treatment (control vs. 
6‑week treated: 1148 ± 58 ms, 14.3 ± 1% vs. 1320 ± 56 ms, 20.3 ± 3%; P = 0.005, < 0.05, respectively). T2 values also 
increased by six weeks of treatment (control vs. 6‑week treated: 16.3 ± 2 ms vs. 10.3 ± 1 ms, P < 0.05). The main histo‑
pathological features were myocardial injury, interstitial fibrosis, inflammation, and edema. The mean vacuolar change 
(%), fibrosis (%), and inflammation score were significantly higher in 6‑week treated rats than in the controls (P = 0.03, 
0.03, 0.02, respectively). In the univariable analysis, vacuolar change showed the highest correlation with native T1 
value (R = 0.60, P < 0.001), and fibrosis showed the highest correlation with ECV value (R = 0.78, P < 0.001). In the mul‑
tiple linear regression analysis model, vacuolar change was a significant factor for change in native T1 (P = 0.01), and 
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Background
Chemotherapy-induced cardiotoxicity is a well-recog-
nized adverse effect of chemotherapy. Anthracyclines 
are the representative agents that cause cardiotoxicity in 
a dose-dependent manner. Many mechanisms of anthra-
cycline cardiotoxicity have been suggested, but the main 
mechanism is thought to involve the iron-dependent 
generation of reactive oxygen species and subsequent 
widespread oxidative damage to cardiomyocyte [1]. This 
results in myofibrillar loss and cellular necrosis and can 
lead to irreversible diffuse myocardial fibrosis [2, 3], 
which is known to be associated with adverse cardiac 
events [4]. Since cardiotoxicity causes irreversible car-
diac damage, early diagnosis and treatment are clinically 
important [5].
Measurement of left ventricular (LV) ejection fraction 
(LVEF) is standard practice for cardiotoxicity monitoring 
during cancer therapy [6, 7]. However, a previous study 
found that the myocardial tissue and cardiovascular mag-
netic resonance (CMR) parameters change before con-
tractile dysfunction and irreversible changes occur [8, 9]. 
Other studies also demonstrated that subclinical myocyte 
injury occurs at lower and intermediate cumulative doses 
with preserved LV systolic function [10–12].
Previous studies have identified histological find-
ings associated with this condition, such as myocardial 
fibrosis and myocyte edema and injury [8, 13–15]. CMR 
could quantitatively evaluate some tissue changes in ani-
mal models of cardiotoxicity [8, 14]. Thus, in the present 
study, we aimed to evaluate histopathologic changes 
associated with anthracycline-induced cardiotoxicity in 
rat models more comprehensively, and validate the native 
T1, extracellular volume (ECV), and T2 values acquired 
using ultrahigh-field T1 mapping CMR against histo-
pathologic features. In addition, we aimed to compare 
native T1, T2, ECV, and histopathologic findings across 
treatment periods.
Material and methods
Experimental design and sample size calculation
All experiments were approved by our institutional 
Animal Care and Use Committee and were performed 
according to the National Institutes of Health guide-
lines [16]. Five control rats that received normal saline 
intravenously (1 mg/kg, twice a week) were consecutively 
included. A total of 40 male Sprague–Dawley rats were 
also consecutively assigned into five specific doxoru-
bicin treatment periods (Groups 1–5): 2-, 4-, 6-, 8-, and 
12-week treatments (cumulative dose: 4, 8, 12, 16, 24 mg/
kg, respectively) with eight rats per treatment period 
(Fig. 1). The sample size estimation was performed using 
PASS software (version 12, NCSS, Kaysville, Utah, USA) 
with a two-sample t-test. Based on a previous study [8], 
we hypothesized that the ECV would be elevated com-
pared to control rats after 3  weeks of treatment. The 
mean ECV and standard deviation and pooled sample 
variance from the previous study were used for the sam-
ple size calculation. A statistical power of 0.80 and type 
I error of 0.05 required 7 rats per group. Considering a 
10% drop out rate, a total of 40 rats (8 in each group) were 
included in this study. Doxorubicin-treated rat models 
were generated by administering doxorubicin (anthracy-
cline agent) to rats (1 mg/kg injection via tail vein, twice 
a week during the treatment periods) under inhalational 
anesthesia.
Cardiovascular magnetic resonance
Rats underwent high field CMR at the end of their spe-
cific treatment periods. Immediately before the CMR 
examination, venous sampling was conducted via the tail 
vein to determine the hematocrit (Hct) of all rats. Inhala-
tional anesthesia was induced using a mixture of oxygen 
and isoflurane.
The CMR examination was performed with a 9.4  T 
scanner (Bruker, Billerica, Massachusetts, USA). The 
protocol included cine, native T1, and T2, and post-
contrast T1 mapping sequences. Cine images in the two- 
and four-chamber long-axis and short-axis planes were 
acquired using a fast low-angle shot sequence with elec-
trocardiographic (ECG) gating and the following param-
eters: echo time/repetition time (TE/TR), 4.0/1.16; flip 
angle, 15°; 25 phases; section thickness, 2  mm; two sig-
nals acquired; acquisition matrix, 128 × 128; and field of 
view, 50 × 50 mm.
Native and post-contrast T1 mapping images were 
acquired before and 15  min after the injection of gad-
oterate meglumine (0.2 mmol/kg body weight, Dotarem; 
Guerbet, Roissy, France) via the tail vein.
vacuolar change and fibrosis were significant factors for change in ECV (P = 0.006, P < 0.001, respectively) by adding 
other histopathological parameters (i.e., inflammation and edema scores)
Conclusions: Quantitative T1 and T2 mapping CMR is a useful non‑invasive tool reflecting subclinical histopathologi‑
cal changes in anthracycline‑induced cardiotoxicity.
Keywords: Magnetic resonance imaging, Myocardial fibrosis, Edema, Inflammation, T1 mapping, Cardiotoxicity, Rats
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T1 and T2 mapping sequences
Native  T1 mapping was performed with the saturation 
recovery Look-Locker sequence due to the high heart 
rate of rats (up to 300–400 bpm) [17]. The detailed pulse 
diagram of the T1 mapping sequence is in the Additional 
file 1. This sequence employed a saturation recovery pulse 
to reset magnetization history at the beginning of acqui-
sition, immediately after ECG triggering. Subsequently, 
saturation recovery-weighted images were acquired 
through a series of several heartbeats by prospective 
ECG-gated cine imaging. The T1 map was obtained by 
pixel-by-pixel estimation of a mono-exponential function 
for each cardiac cycle within the acquisition duration. 
The three-parameter fitting function was: M = A − B*exp 
(− TD/T1)), where M is the signal intensity at saturation 
recovery delay time (TD), and A and B are scale factors. 
Fig. 1 Experimental design and the numbers of subjects in each group. Rats received intravenous doxorubicin (1 mg/kg, twice a week). A total of 
40 rats were consecutively enrolled into five groups (eight rats in each group; group 1: 2‑week, 2: 4‑week, 3: 6‑week, 4: 8‑week, 5: 12‑week). Among 
them, two rats in group 1 and one each in groups 4 and 5 died during the specific treating period. Five control rats (group 0) that received normal 
saline intravenously (1 mg/kg, twice a week) were also included for comparison. Cardiovascular magnetic resonance (CMR) scans (blue circles) 
were performed in the short‑axis planes in each group. All rats were sacrificed for histopathologic evaluation immediately after the CMR scan. The 
association between the CMR parameters and the histopathological changes was assessed
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The parameters were follows: TE/TR, 12/1.35; field of 
view, 50 × 50 mm; acquisition matrix, 128 × 128; section 
thickness, 1.5  mm; number of sections, 3; section gap, 
3 mm (depending on positions of the basal, mid, and api-
cal planes); flip angle, 8°; acquisition duration, 20 heart-
beats; and 10 cardiac phases (depending on the heart 
rate).
T2 mapping was performed using a spin-echo imag-
ing sequence. ECG and respiratory gating were used 
to reduce physiological  motion artifacts. T2 mapping 
parameters were as follows: TR, 1500  ms; TE, 16, 26, 
36 ms; FOV, 50 × 25 mm; matrix, 128 × 64; spatial resolu-
tion, 0.39 × 0.39 mm; excitation slice thickness, 1.5 mm; 
refocusing slice thickness, 3.0  mm; number of slices, 3. 
Pulse sequence diagrams of T2 mapping are in the Addi-
tional file 1.
Image analysis
Two expert radiologists (YJH and CHP) with 11  years 
of experience in cardiovascular image interpretation, 
who were blinded to the group assignment, analyzed the 
images independently. All images were analyzed using 
cvi42 software (Circle Cardiovascular Imaging, Calgary, 
Alberta, Canada).
CMR analysis for left ventricular function and mass 
measurement
LV function, size, and mass were assessed on short-axis 
cine images. First, the endocardial and epicardial borders 
of the LV wall were manually delineated and the contours 
were modified by software on the end-diastolic and end-
systolic images. The LV end-diastolic volume and end-
systolic volume were measured, and the LVEF (%) was 
calculated.
CMR analysis for tissue characterization: T1 and T2 
mapping analysis and ECV calculations
Native T1, post-T1, T2 and ECV values were measured 
at the mid ventricle. On a native T1 image, a post-T1 
image obtained at the mid ventricular level in a short-
axis view, the endocardial and epicardial borders of the 
LV wall were drawn and divided into four segments: 
anterior, inferior, septal, and lateral segments. A 15% 
offset was applied to avoid partial volume artifact. A 
round, < 5  mm2 ROI that avoided the papillary muscle 
was also drawn in the LV cavity (Fig.  2). The myocar-
dial ECV of each segment was automatically calculated 
using the Hct value and the native and post-contrast T1 
values of the LV myocardium and blood cavity using 
the equation in [18].
Evaluation of histopathological features in animal models
After undergoing CMR, each rat was euthanized in 
an unconscious state and placed in a closed  CO2 gas 
chamber. Immediately after euthanasia, the heart was 
removed and fixed in 10% neutral buffered formalin. 
After 1 week of formalin fixation, a cross section of the 
whole heart was sampled along the short axis at the mid 
ventricular level, which was similar to the CMR plane. 
The tissue sections were processed and embedded in 
paraffin. Sections with a 4-µm thickness were cut from 
the paraffin block and stained with hematoxylin and 
eosin (H&E), Masson’s trichrome, and picrosirius red 
stain.
Histopathological features including myocyte injury, 
interstitial fibrosis, inflammation, and edema were evalu-
ated by a pathologist (HSP), blinded to the group assign-
ment and the results of the CMR measurements.
Fig. 2 Measurement of the native T1, post‑T1, and T2 values in the left ventricular (LV) myocardium. The endocardial (red line) and epicardial 
borders (green line) of the LV wall were delineated semi‑automatically; four segments (i.e. anterior, inferior, septal, and lateral segments) were 
delineated automatically by applying 15% offset to avoid partial volume artifacts (white lines). A round < 5‑mm2 region of interest (orange circle) 
was drawn in the LV cavity on pre‑contrast (a) and post‑contrast T1 (b), and T2 (c) mapping images. The extracellular volume fraction (ECV) was 
calculated using the native T1, post‑T1, and hematocrit values
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Quantification of myocyte injury
Myocyte injury was assessed by the presence of intracy-
toplasmic vacuoles in myocytes. Tissue sections from the 
LV were quadrisected into septal, anterior, inferior, and 
lateral segments on a glass slide. The ratio of myocytes 
with cytoplasmic vacuolization to overall myocytes was 
evaluated on a microscopic high-power field (HPF) at a 
magnification of × 200 using a microscope (Olympus 
Corporation, Tokyo, Japan). The number of cells with 
vacuolization per 100 cells was counted. Ten high power 
fields (HPFs) of each LV segment (i.e. anterior, posterior, 
lateral, and septal segment) were evaluated. In total, 40 
HPFs per subject were investigated and the average value 
was used.
Image segmentation and quantification of interstitial 
fibrosis
Interstitial fibrosis was evaluated by determining the 
collagen proportions in the tissue. First, picrosirius red 
stained slides were scanned using a digital slide scan-
ner (Pannoramic SCAN, 3DHISTECH  Ltd., Budapest, 
Hungary). Then, whole area at a magnification of × 200 
was captured in digitized slides using CaseViewer soft-
ware (3DHISTECH Ltd.). Ten areas of each LV segment 
(i.e., anterior, posterior, lateral, and septal segment) 
were selected and 40 microscopic images per rat were 
investigated.
The fraction of fibrosis on each histopathologic image 
was quantified using pixel-based segmentation. Micro-
scopic images in JPEG format were converted from RGB 
into CIE L*a*b space [19, 20] and segmented into three 
clusters: collagen fiber, cardiac muscle, and background, 
using the k-means clustering algorithm [21, 22]. Clus-
tering procedures were internally iterated 100 times in 
order to maximize segmentation accuracy. The degree of 
interstitial fibrosis was calculated based on the total pixel 
number of the collagen fiber cluster. Custom written 
scripts in Matlab 2020a (MathWorks, Natick, Massachu-
setts, USA) were used for the quantification steps.
Inflammation and edema were evaluated by H&E and 
Massons’ trichrome staining. The typical inflammatory 
cell findings (e.g., cells with segmented nuclei for neu-
trophils; cells with the perinuclear hop and clock-face 
chromatin for plasma cells; small dark, round nuclei with 
scanty cytoplasm for lymphocyte, etc.) were considered 
as having inflammation. Widening of the interstitial 
space and pale pink fluid collection and/or surrounding 
inflammation and cellular reaction (e.g. loose fibrosis) 
were considered as edema [23]. Interstitial inflamma-
tion and edema were graded according to the amount of 
inflammatory cells present and an observed increase in 
interstitial space, respectively. The degrees of interstitial 
inflammation and edema in each segment were graded 
according to their degree and then scored (0: absent; 1: 
minimal; 2: mild; 3: moderate; 4: severe). The average 
value of all segments was determined.
Statistical analysis
Continuous variables are expressed as means ± stand-
ard deviations, and categorical variables are expressed 
as frequencies or percentages. The Shapiro–Wilk test 
was performed to evaluate the distribution of the data. 
Comparisons of baseline characteristics, ventricular 
functional parameters, T1 mapping values, and the four 
histopathologic parameters between the groups were 
performed by using a t-test or ANOVA or Kruskal–
Wallis test. Post-hoc analysis was done by Bonferroni 
correction.
The relationship between the T1 mapping parameters 
and relevant histopathological changes was examined by 
a linear regression analysis.
A multiple linear regression model was used to identify 
independent histopathologic factors for changes in native 
T1 and ECV using reconstructed models with all vari-
ables yielding P-values of < 0.05 or a model that excluded 
the lowest correlated variable in previous univariable 
analyses. A P-value of < 0.05 was considered to be statis-
tically significant. All statistical analyses were performed 
using SPSS (version 23.0.0, Statistical Package for the 
Social Sciences, International Business Machines, Inc., 
Armonk, New York, USA).
Results
In total, five control rats, six 2-week treated rats (cumu-
lative dose: 4  mg/kg), eight 4-week treated rats (8  mg/
kg), eight 6-week treated rats (12  mg/kg), seven 8-week 
treated rats (16  mg/kg), and seven 12-week treated rats 
(24  mg/kg) were included in this study. A total of four 
rats (two in group 1 and one each in groups 4 and 5) were 
excluded due to their unexpected deaths during their 
specific treatment periods. CMR was performed after 
each specific treatment period. Immediately after CMR, 
rats were sacrificed for histopathologic evaluations. The 
experimental timeline and the numbers of included and 
excluded rats, and cumulative dose according to the 
treatment periods (Groups 1–5) are shown in Fig. 1.
Physiological and functional data
Compared to control rats, the doxorubicin-treated 
rats showed a significantly lower Hct (58.8 ± 2.0% vs. 
43.3 ± 12.0%, P = 0.001), cardiac output (0.15 ± 0.01  l/
min vs. 0.12 ± 0.03  l/min, P = 0.009), and LVEF (73 ± 4% 
vs. 65 ± 8%, P = 0.03), and a higher LV end-systolic vol-
ume (LVESV) (0.18 ± 0.02 ml vs. 0.24 ± 0.05 ml, P = 0.05). 
LV mass and heart rate were not significantly different 
between the controls and doxorubicin-treated rats. In 
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the subgroup analysis, the LVEF significantly decreased 
in 12-week treated rats (73 ± 4% vs. 59 ± 9%, P = 0.01) 
(Table 1).
T1 and T2 mapping data
In doxorubicin-treated rats, the native T1, ECV, and 
T2 values were higher than in the controls (controls 
vs. doxorubicin-treated rats: 1148 ± 58  ms, 14.3 ± 1%, 
10.3 ± 1  ms vs. 1292 ± 84  ms, 19.7 ± 4.0%, 14.6 ± 3  ms; 
P = 0.001, < 0.001, < 0.05, respectively).
In the subgroup analysis, a comparison of each group 
revealed that the native T1 and ECV values were sig-
nificantly higher in the 6-week treatment (1320 ± 56 ms, 
20.3 ± 3.0%, P = 0.005, < 0.05, respectively), 8-week 
treatment (1327 ± 82  ms, 21.2 ± 4.0%, P = 0.003, 0.01, 
respectively), and 12-week treatment rats (1316 ± 69 ms, 
23.2 ± 4.0%, P = 0.006, 0.001, respectively) than in the 
controls (1148 ± 58  ms, 14.3 ± 1.0%). Although native 
T1 and ECV values in rats treated for longer periods 
were higher than in those treated for shorter periods, 
there were no significant differences amongst treat-
ment periods. T2 values were significantly higher in the 
6-week treated rats than in control rats (16.3 ± 2.0 ms vs. 
10.3 ± 1.0, P = 0.03) (Table 1).
Histopathologic data
Histopathological changes were noted in the doxoru-
bicin-treated rats. The main histopathological findings 
were vacuolar changes in myocytes, interstitial edema, 
inflammation, and fibrosis.
The mean vacuolar changes (range) in groups 1–5 were 
0.5% (0–2.3%), 11.2% (2.4–33.6%), 13.4% (3.9–32.9%), 
12.7% (2.6–35.0%) and 16.5% (8.1–38.0%), respectively. 
The vascular changes in groups 3 (P = 0.03), 4 (P = 0.04), 
and 5 (P = 0.008) were significantly higher than in the 
control rats (0%, 0–0%). The change in group 5 was also 
significantly higher than group 1 (P = 0.01). The mean 
fibrosis (range) in groups 1–5 were 2.2% (1.3–4.1%), 2.1% 
(1.3–3.2%), 4.5% (2.1–14.4%), 6.7% (1.5–21.8%) and 11.0% 
(3.1–25.4%), respectively. The mean fibrosis in groups 3 
(P = 0.03) and 5 (P = 0.001) were significantly higher than 
in the control rats (1.2%, 1.0–1.6%). The median scores of 
inflammation (range) of groups 1–5 were 0.25 (0–0.50), 
1.00 (0–2.00), 1.75 (0.25–3.25), 0.75 (0.25–2.25), and 0.50 
(0–3.25), respectively. The only significant difference 
was noted between group 3 and control rats (P = 0.02). 
Lastly, the median scores of edema (range) of groups 
1–5 were 0.25 (0–1.25), 1.00 (0.25–2.00), 1.25 (0–3.00), 
1.5 (0–3.50), and 1.00 (0–3.00). There was no significant 
difference between groups (Fig.  3). In the univariable 
regression analysis, native T1 value showed significant 
association with the vacuolar change (R = 0.60, P < 0.001), 
myocardial edema score (R = 0.49, P = 0.001), inflamma-
tion score (R = 0.45, P = 0.004), and fibrosis (R = 0.38, 
P = 0.02). ECV showed significant association with 
fibrosis (R = 0.78, P < 0.001), vacuolar change (R = 0.70, 
P < 0.001), myocardial edema (R = 0.42, P = 0.008), and 
inflammation (R = 0.33, P = 0.04) (Fig.  4). The highest 
Table 1 Physiological and cardiovascular magnetic resonance data for all subjects
Values are expressed as mean or mean ± SD
CO cardiac output; ECV extracellular volume fraction; Hct hematocrit; LVEDV left ventricular end-diastolic volume; LVEF left ventricular ejection fraction; LVESV left 
ventricular end-systolic volume; LVSV left ventricular stroke volume, min; minute
*Control vs. Group subjects, P < 0.05



















Hct (%) 58.8 ± 2.0 41.6 ± 13.0 46.3 ± 10.0 40.5 ± 12.0 43.9 ± 12.0 43.0 ± 14.0
Heart rate (min) 281 ± 30 270 ± 24 280 ± 35 271 ± 28 279 ± 51 292 ± 51
LVEDV (ml) 0.69 ± 0.05 0.73 ± 0.09 0.68 ± 0.09 0.77 ± 0.05 0.69 ± 0.09 0.63 ± 0.01
LVESV (ml) 0.18 ± 0.02 0.20 ± 0.04 0.23 ± 0.03 0.27 ± 0.04 0.24 ± 0.06 0.26 ± 0.07
LVSV (ml) 0.51 ± 0.06 0.52 ± 0.06 0.46 ± 0.10 0.50 ± 0.05 0.45 ± 0.07 0.37 ± 0.10
CO (l/min) 0.15 ± 0.01 0.14 ± 0.01 0.13 ± 0.03 0.14 ± 0.03 0.13 ± 0.03 0.10 ± 0.03*
LV mass (g) 0.66 ± 0.08 0.69 ± 0.09 0.67 ± 0.14 0.74 ± 0.11 0.64 ± 0.08 0.61 ± 0.06
LVEF(%) 73 ± 4 72 ± 3 66 ± 8 65 ± 5 65 ± 7 59 ±  9*
Native T1 (ms) 1148 ± 58 1191 ± 119 1278 ± 49 1320 ±  56* 1327 ±  82* 1316 ±  69*
T2 (ms) 10.3 ± 1 12.2 ± 1 11.4 ± 1 16.3 ±  2* 17.3 ± 5 14.0 ± 2
Partition coefficient 0.36 0.28 0.32 0.35 0.38 0.43†
ECV (%) 14.3 ± 1 15.7 ± 1 17.1 ± 2 20.3 ±  3* 21.2 ±  4* 23.2 ±  4*
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correlated parameters were vacuolar change for a native 
T1, and fibrosis for ECV (R = 0.60, 0.78, respectively).
There was no significant associated with a native T1 
in a model with all four histopathologic parameters in 
the multivariable regression analysis. When the low-
est correlated parameter, i.e., fibrosis (R = 0.38), was not 
included in the model, vacuolar change was a significant 
independent factor for changes in the native T1 value 
(P = 0.01) with an adjusted  R2 of 0.34. However, there was 
no improvement in adjusted  R2 compared to the vacu-
olar change for T1 value in the univariable analysis  (R2 of 
0.35). Vacuolar change and fibrosis were significant fac-
tors for changes in ECV (P = 0.006, < 0.001, respectively) 
with an adjusted  R2 of 0.74. By adding other histopatho-
logical parameters (i.e., inflammation and edema scores), 
there was an improvement of  R2 over vacuolar change 
 (R2 of 0.48) or fibrosis  (R2 of 0.60) for ECV in univariable 
analysis (Table  2). When the lowest correlated param-
eter, i.e., inflammation (R = 0.33), was not included in the 
model, vacuolar change and fibrosis were still significant 
factors for changes in ECV (P = 0.004, < 0.001, respec-
tively) with an adjusted  R2 of 0.73.
Fig. 3 Histopathological data for all subjects. The degree of myocardial injury (vacuolar change, a), fibrosis (b), score of myocardial inflammation 
(c), scores of interstitial edema (d) in controls (group 0), and groups 1–5. Groups 1–5 indicate 2‑week, 4‑week, 6‑week, 8‑week, and 12‑week 
treated subjects. Group 1 (2 week), 2 (4 week), 3 (6 week), 4 (8 week), and 5 (12 week) indicate subjects undergoing 2, 4, 6, 8, and 12 weeks of 
treatment. a The mean vacuolar changes (range) in groups 1–5 were 0.5% (0–2.3%), 11.2% (2.4–33.6%), 13.4% (3.9–32.9%), 12.7% (2.6–35.0%) and 
16.5% (8.1–38.0%), respectively. The mean values of vacuolar change were significantly higher in group 3 (P = 0.03), group 4 (P = 0.04), and group 5 
subjects (P = 0.008) than in the control subjects (0%, 0–0%). The mean value of group 5 was also significantly higher than group 1 (P = 0.01). b The 
mean fibrosis (range) in groups 1–5 was 2.2% (1.3–4.1%), 2.1% (1.3–3.2%), 4.5% (2.1–14.4%), 6.7% (1.5–21.8%) and 11. 0% (3.1–25.4%), respectively. 
The mean values of fibrosis were significantly higher in groups 3 (P = 0.03) and 5 (P = 0.001) than in the control rats (1.2%, 1.0–1.6%). c The median 
scores of inflammation (range) of groups 1–5 were 0.25 (0–0.50), 1.00 (0–2.00), 1.75 (0.25–3.25), 0.75 (0.25–2.25), and 0.50 (0–3.25), respectively. There 
was a significant difference only between group 3 and control subjects (P = 0.02). d The median scores of edema (range) of groups 1–5 were 0.25 
(0–1.25), 1.00 (0.25–2.00), 1.25 (0–3.00), 1.5 (0–3.50), and 1.00 (0–3.00), respectively. There was no significant difference between groups
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Discussion
The purpose of this study was to determine the surrogate 
T1 and T2 mapping parameters acquired using ultrahigh-
field T1 CMR against histopathologic features in car-
diotoxicity. We created rat models of cardiotoxicity and 
performed CMR at different treatment time points and 
immediately sacrificed the animals to compare changes 
in CMR and tissue findings. We thoroughly reviewed the 
histopathologic changes that occurred in doxorubicin-
treated and control rats. We also investigated pathologi-
cal factors that are significantly associated with changes 
in T1 and ECV.
Our data demonstrate that the anthracycline agent 
caused various histopathologic changes, which included 
vacuolar changes in myocytes (i.e. myocyte injury), inter-
stitial edema, inflammation, and fibrosis. Additionally, 
most rats exhibited elevated native T1 and ECV values 
with concomitant histopathological changes (Fig. 5). Mild 
vacuolar change was noted early in treatment (4 weeks) 
and significantly changed at 6  weeks. Mild interstitial 
fibrosis was significant change at 6  weeks. Although 
there was no significant difference between doxoru-
bicin-treated groups, vacuolar change and fibrosis were 
more severe in rats treated for longer periods. However, 
myocardial inflammation and edema scores appeared to 
have variations between each group. T1 and ECV values 
were elevated in doxorubicin-treated rats, and both sig-
nificantly changed at 6  weeks. However, LVEF did not 
change significantly until 12 weeks of treatment.
Among histopathological findings, the vacuolar change 
showed the highest correlation with native T1 (R = 0.60), 
and fibrosis showed highest correlation with ECV 
(R = 0.78). In the multivariable analysis model, vacuolar 
change was a significant factor for native T1 changes, and 
vacuolar change and interstitial fibrosis were significant 
factors for ECV changes, which suggests they could be 
valid CMR markers for tissue changes in cardiotoxicity.
Currently, most guidelines use LVEF as a diagnos-
tic indicator for chemotherapy-induced cardiotoxicity. 
However, the main mechanism of cardiotoxicity is micro-
structural injury to the myocardium due to direct effects 
of toxicity [24]. Factors that impair LV systolic function 
do so by either compromising the function of the myofi-
brils, or by injuring or destroying cardiomyocytes [1, 25]. 
The relationship between microstructural injury to the 
myocardium and the course of contractile dysfunction 
remains poorly understood.
A previous study suggested that chemotherapy-
induced cardiotoxicity is considered to be a continuum 
that begins with subclinical myocardial cell injury and 
leads to an early asymptomatic decline in the LVEF that 
can develop into symptomatic heart failure [5]. At the tis-
sue level, early anthracycline toxicity has been associated 
with myocardial inflammation [26–29], vacuolization 
[15, 30, 31], and cell swelling/edema [26, 31, 32]. Later 
stages of toxicity are associated with myocardial fibro-
sis [26, 33, 34]. Our results also supported the observa-
tion that myocardial tissue changes seem to occur at an 
earlier stage. Therefore, LVEF measurement, which does 
not allow for early preventive strategies [7], is a method 
for detecting myocardial damage only after irreversible 
changes have already occurred in the course of a dis-
ease. An effective method for the early detection of myo-
cardial tissue changes is needed. Therefore, we need an 
effective diagnostic tool that can identify the changes in 
these tissues at the early stages of the disease, and T1, 
T2-mapping CMR may be a promising tool. CMR is the 
gold standard technique that allows accurate anatomical 
and functional evaluation [35]. Moreover, myocardial T1 
mapping has become a mainstream sequence in imaging 
various cardiomyopathies, given its quantitative ability 
for tissue characterization. This technique now enables 
us to assess myocardial changes such as myocardial 
edema [36], inflammation [36], or fibrosis, which are rep-
resentative features of anthracycline-induced cardiotox-
icity, by quantifying extracellular matrix expansion using 
ECV measurement [18, 37].
There are a few animal studies that evaluate CMR in 
animal models of cardiotoxicity.
In addition to other studies, we tried to find surrogate 
T1 mapping imaging markers against various histopatho-
logic features in anthracycline-induced cardiotoxicity.
Lightfoot et  al. showed the potential of qualitative 
imaging biomarkers as predictors of cardiotoxicity in 
rats. An early increase in signal intensity can predict the 
subsequent occurrence of cardiotoxicity [38]. Fahad et al. 
[14] performed serial CMR scans in mice. They reported 
an early increase in native T1 and T2 values due to myo-
cardial edema and a subacute increase in ECV due to 
myocardial fibrosis. Both early edema and later fibrosis 
Fig. 4 Univariable regression analysis between native T1 or ECV and histopathological findings. Groups 1 (2 week), gray circle; 2 (4 week), 
emerald circle; 3 (6 week), red circle; 4 (8 week), blue circle; and 5 (12 week), black circle indicates the subjects undergoing 2, 4, 6, 8, and 12 weeks 
of treatment. Group 0 (control), open circle indicates the control subjects. a–d The native T1 value showed significant association with the 
vacuolar change (a, R = 0.60, P < 0.001), fibrosis (b, R = 0.38, P = 0.02), inflammation score (c, R = 0.45, P = 0.004), and myocardial edema score (d, 
R = 0.49, P = 0.001). e–h ECV value showed significant association with the vacuolar change (e, R = 0.70, P < 0.001), fibrosis (f, R = 0.78, P < 0.001), 
inflammation score (g, R = 0.33, P = 0.04), and myocardial edema score (h, R = 0.42, P = 0.008)
(See figure on next page.)
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were predictors of later mortality. Galan-Arriolar et al. [9] 
examined the effects of cardiotoxicity in pigs with intra-
coronary doxorubicin administration. In their study, T2 
values increased in early stages of cardiotoxicity without 
changes in T1 or ECV values. In our study, we focused on 
imaging and histopathologic changes in the earlier period 
and attempted to find which histopathologic changes 
were factors for changes in T1, T2, and ECV values. In 
our results, myocardial edema and inflammation were 
not noted in all treated rats, but were noted in some. 
Changes in T2 values are probably due to myocardial 
edema or inflammation. Changes in T1 and ECV values 
were noted in earlier-treated animals with histologic evi-
dence of cytoplasmic vacuolization of myocytes.
Table 2 Multiple linear regression analysis for the native T1 value and ECV
In each model, all independent variables had no multicollinearity (VIF < 8)
ECV extracellular volume fraction
Bold values indicate statistical significance with P < 0.05
Regression 
coefficient
Standard error P-value VIF R2 Adjusted  R2
Native T1
 Vacuolar change 4.7 1.8 0.01 2.2 0.39 0.34
 Inflammation 21.0 18.2 0.26 1.8
 Edema − 1.7 21.8 0.94 2.9
ECV
 Vacuolar change 0.17 0.06 0.006 3.0 0.76 0.74
 Fibrosis 0.44 0.07  < 0.001 1.4
 Inflammation 0.60 0.52 0.26 1.8
 Edema − 0.39 0.64 0.55 3.0
Fig. 5 CMR data and histopathological findings of doxorubicin‑treated rats. a–c For a representative rat at 6 weeks of doxorubicin treatment 
(group 3) with a left ventricular ejection fraction (LVEF) of 65%, global native T1 of 1401 ms, and ECV of 21.3%, there were marked vacuolar changes 
(arrowheads) of the myocytes with a mean value of 32.9% (a, Masson’s trichrome stain, × 200). Interstitial fibrosis was 3.0% (b, picrosirius red 
stain, × 100). There were interstitial edema (median score: 2) and infiltration of lymphohistiocytic aggregates (arrows, median score: 2) around 
the injured myofibers (c, hematoxylin, and eosin stain, × 200). d–f For a representative rat at 12 weeks of doxorubicin treatment (group 5) with 
a LVEF of 67%, global native T1 of 1410 ms, and ECV of 28.9%, there were multifocal vacuolar degenerations in the myocytes (arrowheads) with 
a mean vacuolar change of 38.0% (d, Masson’s trichrome stain, × 200). Interstitial fibrosis was severe, with a mean value of 25.4% (e, picrosirius 
red stain, × 100). Interstitial edema (median score: 1.75) and scattered lymphocytic infiltration (arrows, median score: 0.25) were also present (f, 
hematoxylin and eosin stain, × 200)
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Similar to the previous results, ECV and T1 values 
significantly changed in the earlier period more so than 
LVEF, and these changes were well-correlated with con-
comitant histopathologic changes. Unlike previous stud-
ies, native T1 changed in the early period, which was 
found to be due to vacuolar change, myocardial inflam-
mation, and edema. As demonstrated in our study, 
anthracyclines are directly toxic to the myocyte, and 
induce myocyte injury as well as inflammation, intersti-
tial edema, and fibrosis.
The myocardial damage and other pathologic changes 
induced by anthracyclines at subclinical doses could not 
be detected by LVEF measurement in many models, 
although it can be quantitatively evaluated using nonin-
vasive native T1-and T2- mapping CMR.
Limitations
There are some limitations to this study. First, T2 map-
ping sequences were conducted in some rats (n = 24). 
It is necessary to find histopathologic factors for T2 
changes in a larger sample size, as was done for native T1 
and ECV. Second, LGE imaging was not possible due to 
the scan time limitation. The LGE pattern of chemother-
apy-induced cardiotoxicity should be verified in future 
studies. Third, in the histopathologic analysis, inflam-
mation and edema scores were qualitative and based on 
the assessment of a single pathologist. Additionally, spe-
cial stains for the quantification of inflammatory cells 
were not conducted. Fourth, the experiment was per-
formed using sample size calculation based on the previ-
ous study, however, given the circumstances, the control 
group has a smaller sample size. Lastly, in our study the 
LVEF decrease was only evident in the 12 week-rats, far 
later than the previous studies which could be an arti-
fact of the wide variability between rats in response to 
the chemotherapy. Additionally, baseline data was not 
acquired before doxorubicin treatment. Further research 
is required to investigate the variability between the 
chemotherapy and the role of quantitative imaging 
parameters including T1 and T2 mapping sequences 
in diagnosing chemotherapy-induced cardiotoxicity in 
human subjects in a clinical setting.
Conclusion
In conclusion, our findings in doxorubicin-treated rats 
suggest that T1 and T2 mapping CMR-based assessment 
of cardiotoxicity may have potential as a non-invasive 
tool for the evaluation of subclinical myocardial changes.
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